CARDIEX

APPENDIX 4D

1.	**Name of Entity**	**Cardiex Limited ACN 113 252 234**
	Half year ended	31 December 2024
	Reporting period	1 July 2024 to 31 December 2024
	Previous period	1 July 2023 to 31 December 2023

2. Results for announcement to the market

		31 December 2024 $	**31 December 2023 $**	**% Change Up (Down)**
2.1	Revenues from continuing operations	1,635,417	9,471,096	(83%)
2.2	Profit/(loss) from continuing operations after tax attributable to members	(6,973,605)	807,254	(964%)
2.3	Net loss attributable to members	(6,973,605)	807,254	(964%)
2.4	Proposed dividends	Nil	Nil	-
2.5	Record date for dividend entitlement	N/A	N/A	-

2.6 Revenues for the period decreased by 83% on a year-on-year basis. The Group has reported a net loss for the period of $6,973,605, compared to a net profit of $807,254 in the previous period. Additional information relating to the Group's operations and results can be found in the Director's report and the half year report for the half year ended 31 December 2024.

		31 December 2024 Cents	**30 June 2024 Cents**	**% Change Up (Down)**
3.	Net tangible asset per security*	1.48 cents	1.18 cents	25%

* Right of Use Assets are included in the NTA calculations

4. The Group did not gain or lose control of an entity during the period.

5. There were no payments of dividends during the reporting period.

6. There is no dividend reinvestment plan in operation.

7. There are no associates or joint venture entities.

8. The Company is not a foreign entity.

9. The Cardiex Limited half year report for the half year ended 31 December 2024 has been subject to review by our external auditors, BDO Audit Pty Ltd. A copy of the independent review report is included in the accompanying half-year report

The Company’s half year report follows.

Yours sincerely,

Niall Cairns
Director
28 February 2025

For more information please contact:

Investor Relations
Rod Hinchcliffe
rod.hinchcliffe@mcpartners.com.au

Media Relations
Melissa Hamilton
melissa.hamilton@mcpartners.com

About Cardiex

Cardiex’s mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company’s market leading SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange (“ASX:CDX”).

CARDIEX LIMITED
AND CONTROLLED ENTITIES

ABN 81 113 252 234

HALF YEAR REPORT

FOR THE 6 MONTHS ENDED 31 DECEMBER 2024

CORPORATE DIRECTORY

DIRECTORS
Mr. Niall Cairns
Mr. Craig Cooper
Mr. King Nelson
Mr. Charlie Taylor

COMPANY SECRETARY
Ms. Louisa Ho

REGISTERED OFFICE AND PRINCIPAL PLACE OF BUSINESS
Suite 301, Level 3
55 Lime Street
Sydney NSW 2000
Telephone: (02) 9874 8761
Email: info@Cardiex.com
Website: www.Cardiex.com

SHARE REGISTRY
Automic Pty Ltd
Level 5/126 Phillip St
Sydney NSW 2000
Telephone: (02) 9698 5414
Website: www.automicgroup.com.au

AUDITOR
BDO Audit Pty Ltd
Level 11, 1 Margaret Street
Sydney NSW 2000
Telephone: (02) 9251 4100
Facsimile: (02) 9240 9821
Website: www.bdo.com.au

CORPORATE ACCOUNTANT
Traverse Accountants
24-26 Kent Street
Millers Point NSW 2000
Website: www.traverseaccountants.com.au

STOCK EXCHANGE LISTING
CardieX Limited's shares are listed on the Australian Securities Exchange (ASX code: CDX).

TABLE OF CONTENTS

LETTER FROM CRAIG COOPER – CHIEF EXECUTIVE OFFICER

Dear Shareholders,

I am pleased to present an update of Cardiex's activities and momentum for the Half-Year ending 31 December 2024. This period has primarily focused on the preparation and launch of CONNEQT Pulse and its supporting digital ecosystem, mainly being, the CONNEQT App. While revenues for the half-year were down on the prior corresponding period, largely due to the settlement associated with the Clinichain clinical trial previously reported, a number of significant milestones were achieved which has the Company well positioned for success and sustained growth in our target health markets.

Following several years of development, we were pleased to place our first commercial order of CONNEQT Pulse devices with our manufacturing partner, Andon - and in a significant achievement, commenced deliveries of these devices towards the end of the period to U.S. customers.

This followed an intense period of marketing and pre-launch activities which resulted in a highly engaged waitlist of over 22,000 signups - and with inventory now in-hand, we're focused on converting this waitlist to sales as we move through the second half of FY25.

Another significant milestone was achieved during the period with the launch of the CONNEQT App. The CONNEQT App forms an integral part of the digital ecosystem developed to support the Pulse and it is now live in the App Store and Google Play Store and available for download in the USA.

The launch of the new CONNEQT products creates significant opportunities for our established pharma business and we are seeing early success through the leveraging of our pharma networks. During the period, we expanded our pharma teams in Europe and APAC and as part of this global push, secured commitments for 1,500 CONNEQT Pulse units across several international markets.

During the half-year, we continued to advance regulatory approvals both in the U.S. and select global markets to ensure we are well placed to meet anticipated demand for our CONNEQT products.

Towards the end of the reporting period, we conducted a capital raising to fund manufacturing, sales and marketing of the Pulse device and ensure we are well positioned for commercial expansion. As part of ongoing efforts to streamline operations for sustainable growth, a number of key changes were made during the period to our engineering and development teams which will not only improve our operational efficiency, but also optimize expenses moving forward.

Looking ahead, we are optimistic about our growth projections. The successful launch and strong early sales momentum of the CONNEQT Pulse, combined with the rollout of the CONNEQT App sets the foundation for further market penetration and revenue growth. We have a strong pipeline of opportunities, and we will continue to leverage our strategic partners to deliver value to our shareholders.

I would like to take this opportunity to thank our dedicated team, partners and shareholders for their continuing support as we execute on our vision to transform cardiovascular health.

Craig Cooper
CEO & Managing Director
Cardiex Limited

OVERVIEW OF OPERATIONS

Cardiex is pleased to announce the following progress for the six-month period, including key updates within the Pharma and CONNEQT business divisions.

1. ***ATCOR UPDATE***

The ATCOR group reported revenue and other income for the half year of $3.29 million. It's worth noting that the prior corresponding period's revenue was significantly boosted by the early settlement of the Clinichain clinical trial (A$7.67 million). Overall however, the ongoing partnership with Clinichain grew in importance to the Company during the period. The Company is now using Clinichain's clinical trial platform to showcase its range of devices - like site-based assessments, 24-hour ABPM, and the CONNEQT Pulse for decentralized trials. During the period, talks also commenced to integrate Cardiex's systems with the largest endpoint technology platform in the pharma industry. There is growing evidence the Company's solutions are being recognized as essential for improving clinical trial efficiency and scalability.

The Company continued to make significant progress on the revenue pipeline for 2025 through strategic engagement with key partners across the pharmaceutical, biotechnology and clinical trial sectors. An important milestone was reached with the conclusion of a compliance audit with a top 5 global clinical research organization ("CRO") which now opens up Cardiex's solutions to their very significant customer base.

During the period, the Company broadened its reach into new therapeutic areas and expanded the pharma teams in Europe and APAC to help with the global push for the new suite of CONNEQT products. While delays are typical in the industry, particularly due to regulatory approvals in some jurisdictions and sponsor approvals, the Company maintained a robust pharmaceutical pipeline at period end of approximately US $8 million, ensuring the business is well-positioned to secure new contracts and meet revenue targets for 2025.

2. ***CONNEQT UPDATE***

CONNEQT Pulse Update

In a significant milestone, the initial order of 8,000 CONNEQT Pulse units was completed by our manufacturing partner, Andon, during the period.

Subsequent to the end of the reporting period, Andon airfreighted 3,000 of the initial Pulse units to the US to commence deliveries, with the remaining 5,000 units arriving in Q1 CY25. The launch of CONNEQT Pulse has demonstrated promising early growth, highlighting strong market demand for arterial health insights and wellness solutions. Separate to the eCommerce efforts and subsequent to period end, our Pharma division secured orders of over 1,500 Pulse units across several international markets.

CONNEQT App Update

As part of the digital ecosystem developed to support the Pulse, during the period the Company launched the CONNEQT App in the USA and it is now live in the App Store and Google Play Store. The CONNEQT App is a key component of the comprehensive arterial health program providing a unique and impactful foundation for fostering healthier outcomes, exemplifying the transformative change and value the Company is delivering to this market.

Some of the key features of the CONNEQT App include; a digital health coach, comprehensive arterial health metrics, guided health programs, educational health content, personalized health cards, device and screen customization and healthcare professional sharing.

Launch of the CONNEQT Arterial Health Assessment

In conjunction with the launch of the Pulse, the Company has also introduced the **CONNEQT Arterial Health Assessment**, a comprehensive package designed to assess and track cardiovascular health. This assessment, priced at US $350, includes the **Pulse device** along with **two (2) Cardiology Reports**, providing a detailed evaluation of arterial function and overall cardiovascular well-being.

OVERVIEW OF OPERATIONS

What the CONNEQT Arterial Health Assessment Offers

The assessment leverages advanced arterial biomarkers monitored by the Pulse, delivering valuable insights to help you take a proactive approach to heart health. These reports (delivered by .pdf to customers over a set period) offer a clear, actionable understanding of your vascular condition, aiding in early risk detection and informed health decisions. Additionally, they serve as a crucial resource for discussions with your physician or cardiologist.

Included Reports:

1. **Risk Profile:**
    - Evaluates your cardiovascular risk levels.
    - Provides personalized recommendations for managing and improving arterial health.
2. **For Your Physician:**
    - Explains arterial stiffness, its measurement, and clinical significance.
    - Summarizes key vascular biomarkers, offering clinical interpretations and potential treatment considerations.
3. **Trending Results:**
    - Tracks changes in your vascular health over time.
    - Provides insights into individual biomarkers, their impact on cardiovascular risk, and comparisons with optimal ranges.

Integration with the CONNEQT App

The **CONNEQT App** enhances this process by transforming complex vascular data into actionable recommendations. It enables users to monitor trends, optimize heart health, and make informed lifestyle choices based on their results.

Future Expansion

With the initial purchase of the Assessment, users receive **two (2) complimentary reports**. Moving forward, the Company plans to introduce a continuous arterial monitoring service, allowing users to purchase additional reports for ongoing cardiovascular tracking—*a strategy that fosters long-term customer engagement and a revenue stream beyond a one-time sale.*

For more details, visit: https://conneqthealth.com/

CONNEQT Wearable Technology Update

During the period, the Company completed the first phase of the clinical validation study for the CONNEQT band technology in partnership with Macquarie University's Blood Pressure and Arterial Function (BPAF) Laboratory. This study focused on validating the band technology performance through a direct comparison with Cardiex's industry standard XCEL device. Achieving alignment with XCEL's well-established metrics is a critical step in ensuring the capability to deliver clinical-grade accuracy in a wearable device. The success of this phase provides the foundation for the next steps and underscores the potential of our wearable technology to set a new standard in arterial health monitoring.

RADx® Grant Funding

During the period, the Company was pleased to be selected as one of five grand prize winners in the final phase of the National Institutes of Health's (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech for Maternal Health Challenge (The Challenge).

The Company had previously passed the 'Initial Assessment' and 'Interim Milestone' phases of the Challenge and had secured a total of US$415,000 in cash grants. Cardiex was then selected to participate in the final phase of the Challenge, and after being announced as one of five winners, secured a further US$525,000 in cash grant funding.

Regulatory Update

During the period, the Company continued with preparations for FDA clearance submission on OTC for the CONNEQT Pulse. Initial customer usage data on the Pulse forms an important part of this submission and the Company is collating this information as part of the overall submission.

The Company also continues to actively work on expanding registrations and clearances for the Pulse across multiple new markets, including receiving TGA approval in Australia, Medsafe in NZ and CE approval in Europe, all of which are expected to be lodged in calendar 2025. Additionally, a review of registration requirements in Indonesia, Malaysia and Singapore commenced following strong inbound interest received for all our products in these countries.

3. ***CORPORATE ACTIVITIES***

Funding Activities

(a) Capital Raising

In December, the Company completed a Placement of 36,111,112 new fully paid ordinary shares at $0.09 per share to institutional and sophisticated investors to raise $3.25 million (before costs). Director participation in the Placement totalled $325k, which is subject to shareholder approval at an EGM to be held in H2 FY25. Participants in the Placement received one free attaching listed option for every new share issued. These listed options trade under the existing class CDXOA.ASX and are exercisable at $0.20, expiring on or before 30 November 2025.

Funds from the placement are largely being used for new device manufacturing, marketing and sales activities, and for commercial expansion, including scaling up supply chain operations for the CONNEQT Pulse device.

(b) Funding Commitment Agreement

In December, the Company issued 75,000,000 shares in full satisfaction of the $6 million invested by C2 Ventures, the entity associated with Directors Niall Cairns and Craig Cooper, under the Funding Commitment Agreement (FCA). $5.48 million was contributed in cash, with the balance relating to the settlement of Employee and Directors benefits owed to Mr. Craig Cooper and Mr. Niall Cairns.

(c) Extended Finance Facilities

In August, the Company announced it had entered into a new R&D Term Loan Facility with Mitchell Asset Management (MAM) and when combined with an existing Working Capital Facility with MAM, took the total principal amount outstanding with MAM to $2 million exclusive of any interest owed or charges.

MAM R&D Term Loan Facility

The new R&D Term Loan Facility of $1.12 million with MAM was advanced as a prepayment of forecast Research and Development Tax Incentives that are due to be received by the Company for the 30 June 2024 and 30 June 2025 financial years.

MAM Working Capital Facility

The Company also held an existing short-term working capital facility of $880,000 with MAM which had an extended maturity date of 31 October 2024 or the date of the receipt of the R&D Tax Incentive refund.

The extension of the MAM Working Capital Facility provided the opportunity for the Company to lodge its FY24 R&D Tax Incentive, which based on prior lodgment history, would allow the Company to repay all the MAM facilities within their maturity dates.

During the period, Cardiex received approval from AusIndustry for the inclusion of overseas software development costs in its R&D Tax Incentive claims for FY2024-FY2026.

OVERVIEW OF OPERATIONS

Post period end, the Company received a total refund of $1.46 million in relation to FY2024, a significant increase from prior year claims. Upon receipt, the funds were used towards full repayment of the MAM Working Capital Facility and partial repayment of the MAM R&D Term Loan Facility, which was reduced to $730k. The forecasted 2025 R&D Tax Incentive refund is expected to be in line with the FY2024 refund and be received before 31 October 2025.

Streamlining Operations for Sustainable Growth

The Company is focused on new product launches with CONNEQT and positioning the Pharma business for growth, while at the same time is committed to reducing cash burn and streamlining operational expenses. Post period end there has been a significant restructuring of operations to improve efficiencies and cost savings.

Key changes included centralizing the engineering and development teams in the Sydney office as part of the Company's 'return to office' policy. This has involved transitioning from a predominantly U.S.-based remote workforce, compensated in USD, to a centrally managed team located in Sydney. This move not only aligns with operational strategy, but also delivers substantial management efficiencies and cost savings, particularly given the strength of the USD.

Additionally, the Company has significantly reduced its reliance on a Americas-based outsourced engineering contractor by also shifting much of that work to Sydney. This change further enhances efficiency and contributes to meaningful cost reductions, strengthening the financial position of the Company while maintaining high-quality output.

Once fully implemented, these changes are expected to deliver significant cost savings during H2 FY25. An overall saving of approximately US$ 1 million is expected over CY25 whilst also enhancing Australian R&D rebates. These measures will enhance operational efficiency and support the Company's broader goal of driving sustainable growth while optimizing expenses.

Extraordinary General Meeting of Shareholders

Subsequent to period end, Cardiex will call an Extraordinary General Meeting (EGM) seeking shareholder approval of resolutions relating to related party participation in the December 2024 Placement and refreshment of the Company's placement capacity.

DIRECTORS' REPORT

The Directors present their report for the half-year ended 31 December 2024.

Directors

The following persons held office as Directors of Cardiex Limited at any time during or since the end of the reporting period, unless stated otherwise:

Mr. Niall Cairns – Executive Chairman and Director

Mr. Craig Cooper – Executive Director, Chief Executive Officer

Mr. King Nelson – Non-Executive Director

Mr. Charlie Taylor – Non-Executive Director

Company Secretary

Ms. Louisa Ho

Review of Operations

Revenue and Expenses
The Group generated total revenue and other income of $3,293,069, down 69% from $10,510,621 in the previous half-year period. This decrease includes $7.67m in prior period revenue relating to the cancelled Clinichain clinical trial, which was settled with the Group in December 2023.

The Group's net loss for the period attributable to members amounted to $6,973,605 (31 December 2023: profit of $807,254), largely due to the decrease in revenue as well as the following:

- An increase of $220,508 (288%) in marketing and sales expenses, primarily due to go-to-mark costs incurred for the CONNEQT Pulse.
- A $687,365 (35%) decrease in administration expenses, primarily due to additional costs relating to the US listing and ASX re-compliance in the prior period.
- A decrease of $152,432 (25%) in interest expense, due to interest incurred on convertible notes facilities held in the prior period.
- An increase of $616,583 in share-based payments (non-cash), due to recognition of vesting expenses on options and performance rights. The prior period included a reversal of vesting expenses relating to performance rights that vested upon an US listing, resulting in a large movement between the periods.
- A $683,003 fair value loss (2023: $406,606), primarily due to fair value movements to Cardiex's InHealth Convertible Note and InHealth equity investment.
- A bad debts expense of $268,474 recognised in the period for debtors outside of 90 days. The Group are still actively pursuing these amounts, and expect partial or full collection.

Statement of Financial Position
The Group's Balance Sheet has strengthened during the period, with large increases in Current Assets. This has been driven by a combination of factors that are outlined below:

- Current Assets increased by $4,351,986 (42%) during the period, as follows:
  - Cash and cash equivalents increased by $2,918,924 (606%), primarily due to cash receipts from a Placement completed in December 2024, as well as drawdowns on the Funding Commitment Agreement.
  - Trade and other receivables increased by 89% to $312,445 due to strong sales in the month of December 2024.
  - Other current assets have increased by 75% to $1,584,835, primarily due to receivables recognised from the FY2024 and FY2025 research and development tax incentive.
- Current Liabilities increased in the period, driven by:
  - A 127% increase in borrowings to $2,000,000, due to a new R&D Funding Facility entered into in the period with Mitchell Asset Management.

- During the year, Cardiex issued 111,055,970 new shares as follows:
  - 32,500,000 shares upon the completion of a placement raising $2,925,000. Cardiex Directors have committed a further $325,000 the Group as part of the placement, subject to shareholder approval.
  - 75,000,000 shares issued to C2 Ventures Pty Ltd upon the conversion of the Funding Commitment Agreement drawdowns.
  - 1,305,970 shares issued to suppliers and employees.
  - 2,250,000 shares upon the conversion of performance rights.
- As a result of the above, the Group's strengthened Statement of Financial Position shows net assets of $6,600,445 (30 June 2024: $4,087,481).

Cashflows

- Net cash outflows from operating activities decreased to $5,970,005 (2023: cash inflows of $1,414,195). The decrease is primarily due to cash receipts from the Clinichain clinical trial in the prior period.
- Net cash provided by financing activities was $8,981,578 (2023: $2,172,597), as required by the Group to support its growth initiatives.

Refer to the overview of operations on page 4 for a comprehensive update on operations during the period.

Principal Activities

During the period the principal continuing activities of the Group consisted of designing, manufacturing and marketing medical devices for use in cardiovascular health management, and the development of clinical and consumer digital health solutions.

Dividends

No dividends were paid or declared by the Group since the end of the previous financial year and the Directors do not recommend dividends be paid for the half year ended 31 December 2024.

Significant Changes in the State of Affairs

There were no significant changes in the state of affairs of the Group during the period.

Likely Developments and Expected Results of Operations

The Group will continue to focus on its core business strategy of developing and selling medical and home health care devices and digital solutions for hypertension, cardiovascular disease, and other vasuclar health disorders. The Group is positioned to build on the strong momentum from FY24 and H1 2025, with a key focus on the launch of the CONNEQT Pulse, and the performance of its pharmaceutical sales division.

Matters Subsequent to Period End

Subsequent to the balance date the Group announced the following material events:

- On 9 January 2025, Cardiex received its 2024 R&D Tax Incentive refund totalling $1.46m. The funds were used to fully repay the Group's working capital loan facility and partially repay the R&D Term Loan Facility.
- On 23 January 2025, Cardiex announced that deliveries to customers of CONNEQT Pulse units had commenced upon receipt of the first 3,000 units from manufacturing partner, Andon.

No other significant subsequent event has arisen that significantly affects the operations of the Group.

Rounding of Accounts

The Company has applied the relief available under ASIC legislative Instrument 2016/191 and accordingly, amounts in the financial statements and Directors' report have been rounded to the nearest dollar.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 11.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the Directors:

Niall Cairns

Executive Chairman

Sydney, 28 February 2025

Tel: +61 2 9251 4100
Fax: +61 2 9240 9821
www.bdo.com.au

Level 11, 1 Margaret St
Sydney NSW 2000
Australia

DECLARATION OF INDEPENDENCE BY TIM AMAN TO THE DIRECTORS OF CARDIEX LIMITED

As lead auditor for the review of CardieX Limited for the half-year ended 31 December 2024, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
2. No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of CardieX Limited and the entities it controlled during the period.

Tim Aman
Director

BDO Audit Pty Ltd

Sydney, 28 February 2025

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE HALF YEAR ENDED 31 DECEMBER 2024

	Note	31 Dec 2024	31 Dec 2023
Revenue	2	$ 1,635,417	$ 9,471,096
Other income	3	1,657,652	1,049,525
Total revenue & other income		**3,293,069**	**10,520,621**
Cost of goods sold		(383,799)	(344,216)
Bad debts expense		(268,474)	(16,405)
Marketing and sales expense		(297,123)	(76,615)
Product development and regulatory expense		(1,336,349)	(1,312,564)
Occupancy expense		(143,616)	(141,344)
Employee benefits expense		(4,932,759)	(4,817,043)
Share based payments expense		(594,647)	21,936
Administration expense	4	(1,250,581)	(1,937,946)
Interest expense		(455,637)	(608,069)
Foreign exchange gain/(loss)		79,314	(74,495)
Fair value loss on investments		(618,041)	(1,185,753)
Fair value gain/(loss) on financial assets and liabilities	16	(64,962)	779,147
Total expenses		**(10,266,674)**	**(9,713,367)**
Net (loss)/profit before income tax expense		**(6,973,605)**	**807,254**
Income tax expense		-	-
Net (loss)/profit for the period		**$ (6,973,605)**	**$ 807,254**
Other comprehensive income/(loss) for the period, net of tax – Exchange differences on translation to the presentation currency		16,187	(157,000)
Total comprehensive (loss)/income for the period attributable to the members of Cardiex Limited		**$ (6,957,418)**	**$ 650,254**
Profit/(loss) per share attributable to the members of Cardiex Limited:			
Basic and diluted (loss)/profit per share (cents)	5	$ (2.4)	$ 0.6
Diluted (loss)/profit per share (cents)	5	$ (2.4)	$ 0.6

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2024

	Note	31 Dec 2024	30 Jun 2024
Assets			
Current assets			
Cash and cash equivalents		$ 3,400,356	$ 481,429
Trade and other receivables		663,432	350,987
Inventory		2,472,678	2,553,503
Financial assets	7	4,486,773	4,870,169
Other current assets	6	3,706,619	2,121,784
Total current assets		**14,729,858**	**10,377,872**
Non-current assets			
Property, plant and equipment		1,089,390	1,215,816
Intangible assets		619,180	619,701
Financial assets	7	462,780	392,854
Other non-current assets	6	85,546	43,551
Total non-current assets		**2,256,896**	**2,271,922**
Total assets		**$ 16,986,754**	**$ 12,649,794**
Liabilities			
Current liabilities			
Trade and other payables		$ 4,176,985	$ 3,890,519
Unearned revenue	8	465,399	309,353
Provisions		488,818	490,604
Financial liabilities	9	2,673,858	2,347,751
Lease liabilities		179,073	158,920
Borrowings	10	2,000,000	880,000
Total current liabilities		**$ 9,984,133**	**$ 8,077,147**
Non-current liabilities			
Provisions		8,317	8,976
Lease liabilities		393,859	476,190
Total non-current liabilities		**402,176**	**485,166**
Total liabilities		**$ 10,386,309**	**$ 8,562,313**
Net assets		**$ 6,600,445**	**$ 4,087,481**
Contributed equity	11	$ 97,618,506	$ 88,108,332
Reserves		2,646,234	2,669,839
Accumulated losses	12	(93,664,295)	(86,690,690)
Total equity		**$ 6,600,445**	**$ 4,087,481**

The above consolidated statement of financial position should be read in conjunction with the accompanying notes.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE HALF YEAR ENDED 31 DECEMBER 2024

	Note	Contributed equity	Reserves	Accumulated losses	Total equity
Balance at 1 July 2023		**76,615,802**	**$ 6,389,306**	**$ (83,753,513)**	**$ (748,405)**
Profit after income tax expense for the period		-	-	807,254	807,254
Other comprehensive loss for the period, net of tax		-	(157,000)	-	(157,000)
Total comprehensive income for the period		**$ -**	**$ (157,000)**	**$ 807,254**	**$ 650,254**
Transactions with owners in their capacity as owners:					
Shares issued in lieu of payments to suppliers	11	65,401	-	-	65,401
Costs of issuing share capital	11	(24,555)	-	-	(24,555)
Share based payments	11	-	(21,936)	-	(21,936)
Options issuable for convertible notes	11	-	100,953	-	100,953
Performance rights expired	11	-	(3,288,176)	3,288,176	-
Balance at 31 December 2023		**$ 76,656,648**	**$ 3,023,147**	**$ (79,658,083)**	**$ 21,712**
Balance at 1 July 2024		**$ 88,108,332**	**$ 2,669,839**	**$ (86,690,690)**	**$ 4,087,481**
Loss after income tax expense for the period		-	-	(6,973,605)	(6,973,605)
Other comprehensive loss for the period, net of tax		-	16,187	-	16,187
Total comprehensive loss for the period		**$ -**	**$ 16,187**	**$ (6,973,605)**	**$ (6,957,418)**
Transactions with owners in their capacity as owners:					
Capital placement	11	2,925,000	-	-	2,925,000
Shares issued on conversion of Funding Commitment Agreement	11	6,000,000	-	-	6,000,000
Shares issued on exercise of performance rights	11	691,875	(691,875)	-	-
Shares issued in lieu of payments to employees	11	79,291	-	-	79,291
Shares issued in lieu of payments to suppliers	11	29,851	-	-	29,851
Costs of issuing share capital	11	(215,843)	-	-	(215,843)
Share based payments	11	-	652,083	-	652,083
Balance at 31 December 2024		**$ 97,618,506**	**$ 2,646,234**	**$ (93,664,295)**	**$ 6,600,445**

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE HALF YEAR ENDED 31 DECEMBER 2024

	Note		31 Dec 2024		31 Dec 2023
Cash flows from operating activities					
Receipts from customers		$	1,179,297	$	8,532,218
Payments to suppliers and employees			(7,944,607)		(7,662,864)
Cash receipts from other income			795,305		544,841
Net cash (used in)/from operating activities		**$**	**(5,970,005)**	**$**	**1,414,195**
Cash flows used in investing activities					
Payments for property, plant and equipment			-		(7,705)
Net cash used in investing activities		**$**	**-**	**$**	**(7,705)**
Cash flows from financing activities					
Proceeds from shares issued	11		2,785,000		-
Share issue costs paid	11		(215,843)		(24,555)
Proceeds from Funding Commitment Agreement	11		5,478,766		-
Proceeds from issue of convertible debt	9		-		1,445,000
Proceeds from share applications	9		-		867,457
Borrowings received	10		1,120,000		-
Interest paid			(145,495)		-
Borrowing costs			(15,070)		
Lease principal repayments			(115,780)		(115,305)
Net cash from financing activities		**$**	**8,891,578**	**$**	**2,172,597**
Net increase in cash and cash equivalents			**2,921,573**		**3,579,087**
Cash and cash equivalents at the beginning of the fiscal period			481,429		716,319
Effects of foreign currency exchange on cash and cash equivalents			(2,646)		910
Cash and cash equivalents at the end of the period		**$**	**3,400,356**	**$**	**4,296,316**

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF YEAR ENDED 31 DECEMBER 2024

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PREPARATION

These condensed general purpose financial statements represent those of Cardiex Limited ("Cardiex") for the interim half year reporting period ended 31 December 2024 and its controlled entities (the "consolidated group" or "group") and have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'. The separate financial statements of the parent entity, Cardiex Limited, have not been presented within this financial report pursuant to the Corporations Act 2001.

These condensed general purpose financial statements do not include all the notes of the type normally included in annual financial statements. These financial statements are to be read in conjunction with the annual report for the year ended 30 June 2024 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

GOING CONCERN

The financial statements have been prepared on the going concern basis, which contemplates continuity of normal business activities and the realisation of assets and the discharge of liabilities in the normal course of business.

As disclosed in the financial statements, the Group incurred a loss after tax for the period of $6,973,605 (2023: profit of $807,254), had a net asset position of $6,600,445 (30 June 2024: $4,087,481) and had net cash outflows from operating activities of $5,970,005 (2023: net cash inflows of $1,414,195).

The Company has encountered challenges in relation to its financial performance, having incurred operating losses in the past, and there is no certainty that it will achieve or maintain profitability in the future. There are a number of risks to the Company's commercial operations which, if any one or more of them occur, could adversely affect the Company's business, financial condition, and operating results. These risks include, but are not limited to:

(i) Failure of the Company's SphygmoCor technology-enabled products, from which the majority of the Company's revenue is currently derived, to gain market acceptance.
(ii) The Company's limited operating history with certain products, which makes it challenging to predict long-term performance based solely on historical financial results.
(iii) Accurate demand forecasting for products and effective inventory management are crucial for the Company's financial success. Increases in component costs, supply shortages, and supply changes could disrupt the supply chain.
(iv) The inability to anticipate appropriate pricing levels for its products, and economic downturns or uncertainties could reduce consumer discretionary spending and demand for its products and services.
(v) Consolidation in the healthcare industry may result in demands for price concessions or the exclusion of existing market participants from certain markets.
(vi) Inefficient management of growth and expansion, including cost-effective and timely scaling of operations.

The cash flow forecast prepared for the assessment of Going Concern factors in a number of estimates and judgements. These relate to cash flows which are subject to variation in the timing and quantum of revenue, which is dependent on the successful launch of new products, expenditure, debt repayments, and grant income. It also contemplates the need to raise capital by way of equity funding. The above matters, in conjunction with the risks highlighted, give rise to a material uncertainty that may cast significant doubt over the ability of the Group to continue as a going concern.

During the period, the Group was successful in raising $3.25m (before costs) by way of a Placement to institutional, family office, and sophisticated investors. The Group also received a further $5.5m in cash receipts from the Funding Commitment Agreement with C2 Ventures Pty Ltd, a Company jointly owned by Directors Niall Cairns and Craig Cooper.

The Directors are of the opinion that there are reasonable grounds that the Group will be able to continue as a going concern, after consideration of the following factors:

- During the period $5.5m in drawdowns were received from the Funding Commitment Agreement entered into with C2 Ventures Pty Ltd, with a further $0.5m allocated to outstanding Directors invoices.
- Cardiex continues to conduct a strategic review to streamline its operations and continues to take measures to reduce cash outgoings for employee benefits, product development costs, and administration costs. There were

significant costs incurred in FY2023 and FY2024 relating to the development and subsequent FDA clearance of the CONNEQT Pulse, the withdrawn US listing, and subsequent re-compliance with the ASX that have since been curtailed.

- Deliveries of the CONNEQT Pulse device commenced in Q3 of FY2025, providing the Group with additional revenue from a new product line.
- During the period, Cardiex received approval from AusIndustry for the inclusion of overseas software development costs in its R&D Tax Incentive claims for FY2024-FY2026. A refund of $1.46 million was received post period end, a significant increase from prior year claims. This is secured against Cardiex's R&D funding facility with Mitchell Asset Management, of which there is currently $730k repayable, and the Group may consider extending this facility against the following years R&D claim. The FY2025 refund is expected to be in line with that of FY2024, which far exceeds the current balance of the R&D funding facility.
- There is currently a robust pipeline for deploying devices and services in large-scale clinical trials.
- The Group has a successful track record of being able to raise both equity and debt financing and are prepared to raise additional funds if required. Preliminary discussions have taken place with various debt funders and equity providers both in Australia and the US, which may be required to progress further should sales of the CONNEQT Pulse be lower than anticipated, or if there are delays to clinical trial cash flows.

The Directors are of the opinion that the Group will be successful in managing the above matters and accordingly, they have prepared the financial report on a going concern basis. At this time, the Directors are of the opinion that no asset is likely to be realised for an amount less than the amount at which it is recorded in the consolidated financial report as at 31 December 2024. However, should the above not eventuate, the Group may be unable to realise its assets and discharge its liabilities and commitments in the normal course of business and at the amount stated in the financial report

Accordingly, no adjustments have been made to the financial report relating to the recoverability and classification of the asset carrying amounts or the amounts and classification of liabilities that might be necessary should the Group not continue as a going concern.

NOTE 2. REVENUE

Revenue consists of the following:

		31 Dec 2024		31 Dec 2023
Sale of goods revenue	$	1,395,327	$	1,507,328
Lease revenue[1]		127,444		7,866,924
Service revenue		85,688		72,529
Freight revenue		26,958		24,315
	$	**1,635,417**	**$**	**9,471,096**

1. The prior period lease revenue includes $7.67m in revenue relating to the cancelled Clinichain clinical trial. Cardiex received full cash settlement of all contractual payments for the trial in December 2023, totalling $6.26m.

NOTE 3. OTHER INCOME

Other income consists of the following:

		31 Dec 2024		31 Dec 2023
Research and development tax incentive scheme	$	859,478	$	377,731
Interest income		2,150		139,808
Grant and award income		793,155		490,337
Miscellaneous other income		2,869		41,649
	$	**1,657,652**	**$**	**1,049,525**

NOTE 4. EXPENSES

Net loss before income tax expense includes the following specific expenses:

	31 Dec 2024	31 Dec 2023
Administration expense		
Professional fees associated with US listing	$ -	$ 438,460
Other professional fees	804,527	1,062,485
Other administration expenses	446,054	437,001
	$ 1,250,581	**$ 1,937,946**

NOTE 5. EARNINGS PER SHARE

The calculation of the basic and diluted profit/(loss) per share is based on the following information:

	31 Dec 2024	31 Dec 2023
Reconciliation of earnings used in calculating earnings per share		
Net (loss)/profit after tax	$ (6,973,605)	$ 807,254

	No. of shares	No. of shares
Weighted average number of ordinary shares outstanding during the period used in calculating basic earnings per share	**296,222,893**	**143,642,056**
Weighted average number of ordinary shares outstanding during the period used in calculating diluted earnings per share	**296,222,893**	**188,892,056**
Basic (loss)/profit per share (cents)	**$ (2.4)**	**$ 0.6**
Diluted (loss)/profit per share (cents)	**(2.4)**	**0.6**

NOTE 6. OTHER ASSETS

Other assets consisted of the following:

	31 Dec 2024	30 Jun 2024
Current		
Prepaid expenses	$ 1,279,357	686,560
Placement funds in transit	140,000	-
Research and development tax incentive receivable (Note 3)	2,259,283[1]	1,399,806
Deposits	27,979	35,418
	$ 3,706,619	**$ 2,121,784**
Non-current		
Deposits	85,546	43,551
	$ 85,546	**$ 43,551**

1. $1,455,105 relates to the FY2024 R&D tax incentive, received in January 2025, and $804,178 relates to accrued income for the FY2025 R&D tax incentive.

NOTE 7. FINANCIAL ASSETS

Financial assets consisted of the following:

		31 Dec 2024		30 Jun 2024
Current				
inHealth Medical Services convertible note (a)	$	4,486,773	$	4,870,169
	$	**4,486,773**		**4,870,169**
Non-current				
inHealth Medical Services investment (a)		462,780		392,854
	$	**462,780**	**$**	**392,854**
Total financial assets	**$**	**4,949,553**	**$**	**5,263,023**

(a) inHealth Medical Services investment & convertible note

- On 31 January 2019, the Company exercised in full its option under the agreement to purchase US$3,000,000 of inHealth Medical Services "Tranche 2" (T2) Convertible Note (the "inHealth Note") securities.
- Both the debt and derivative components of the inHealth Note are measured as a single instrument at FVTPL as there is an embedded conversion feature. It is measured at FVTPL as a single instrument to significantly reduce any measurement or recognition inconsistencies that would arise from other methods.
- By 31 December 2019, the Company had paid the full US$3,000,000 to inHealth under the Agreement for the T2 Notes.
- In July 2020, the Company and inHealth had signed an agreement to restructure the partnership. Key changes were reducing the outstanding convertible note to US$2,500,000 by repayment of US$500,000, extending the maturity date to 1 July 2021, and exchanging the option to move to 50.5% for the issuance of 1% of the fully diluted equity of inHealth.
- In July 2021 it was agreed to further extend the maturity date of the convertible note to 31 December 2021 and further agreed between the parties to forgive accrued interest up until 30 June 2020 totalling A$338,373 in return for a further 1% of fully diluted equity of inHealth to Cardiex.
- In March 2022, the inHealth Note was extended to November 2023, incorporating all interest for the period 1 July 2021 to 28 February 2022 to the principal value of the inHealth Note totalling US$2,875,317. Following the end of this term, the Note maturity was further extended to 31 May 2024.
- Prior to the balance date, the Cardiex Board commenced discussions with inHealth regarding its options following the extended maturity date of 31 May 2024. No extension had been formally set while these discussions are ongoing. Since balance date and up until the date of this report, Cardiex and InHealth have continued to negotiate terms in relation to converting the Notes to Preference Shares. Negotiations are expected to be completed shortly, and an announcement will be made once the transaction is completed.
- Due to the ongoing negotiations, the Convertible Note investments do not qualify for derecognition during the reporting period ended 31 December 2024 as the contractual cash flows from the financial asset have not expired and the entity has not transferred the asset.
- At the balance date of 30 June 2024, the total convertible note asset was fair valued by an external expert at A$4.87m (US$3.23m). The external valuers used a Black-Scholes Calculation for Option-Pricing Model to value the proposed preference shares, based on conversion of current principal and interest. The fair value of the Notes at 30 June 2024 were subsequently deemed to be the lower of
    - The face value of the Notes plus interest, being A$4,940,222.
    - The present value of the proposed preference shares derived from the Black-Scholes Calculation for Option-Pricing Model, being A$4,870,169.

  A discounted cash flow valuation for InHealth was also prepared by the external valuers, as required for the inputs into the valuation and calculation of Cardiex's equity interest in InHealth.
- Subsequent to period end, Cardiex and InHealth management agreed draft final terms for the conversion of the convertible note to participating preference shares. It was agreed that the preference shares will receive 15% of any distribution made to shareholders, and Cardiex remain entitled to receive the full face value of the converted debt of US$3,117,344. As at the date of this report, no formal agreement had been signed
- At the balance date of 31 December 2024, the total convertible note asset was fair valued by management at A$4,486,773. The valuation was prepared using the same metrics used at 30 June 2024, and adjusted to take into consideration the latest discussed agreed terms of the conversion. During the period, a fair value loss of A$659,562 and foreign exchange gain of A$276,166 was recognised.
- As at 31 December 2024, the Company holds 7.64% equity in inHealth Medical Services, Inc, currently valued at A$462,780 (30 June 2024: A$392,854), based on an equity value of A$3.77m, (US$6.06m).

NOTE 8. UNEARNED REVENUE

Unearned revenue consisted of the following:

		31 Dec 2024		30 Jun 2024
Advances received from clinical trial contracts	$	116,841	$	109,662
Unearned revenue from sales of goods		109,578		-
Unearned revenue from customer service contracts		238,980		199,691
	$	**465,399**	**$**	**309,353**

NOTE 9. FINANCIAL LIABILITIES

Financial liabilities consisted of the following:

		31 Dec 2024		30 Jun 2024
Promissory Note	$	2,568,344	$	2,347,751
Accrued interest on Funding Commitment Agreement		105,514		-
	$	**2,673,858**	**$**	**2,347,751**

Promissory note

On 7 November 2023, Cardiex entered into a Promissory Note with Wilson Sonsini Goodrich & Rosati, Professional Corporation for a principal sum of US$1,500,000. This amount reflects the balance owing of US legal fees in relation to the US listing, post a credit received of US$731,950 (A$1,104,997). The Promissory Note attracts an interest rate of 5.5% and is repayable on the earliest of:

a) 20 April 2025 (subsequently renegotiated per terms outlined below);
b) the closing of debt financing or equity financing of Cardiex after 1 January 2024, the gross proceeds of which equal or exceeds US$6,000,000;
c) the closing of a change of control transaction;
d) the Company becomes cash flow positive and is in a position to make payment of the outstanding invoices;
e) upon the occurrence of an event of default.

During the period, repayment terms have been renegotiated to the following:

- US$250k before 31 January 2025. This payment was completed subsequent to balance date.
- US$250k before 31 July 2025.
- The final balance repayable by 31 October 2025.

Funding Commitment Agreement

Refer Note 17 for detailed disclosure.

NOTE 10. BORROWINGS

Borrowings includes the following liabilities carried at amortised cost:

		31 Dec 2024		30 Jun 2024
R&D loan facility	$	1,120,000	$	-
Working capital loan facility		880,000		880,000
	$	**2,000,000**	**$**	**880,000**

Working capital loan facility

In December 2022, wholly owned subsidiary Atcor Medical Pty Ltd entered into a working capital loan facility for up to $880,000, to support product and development expansion initiatives. The facility attracts an interest rate of 1.33% per calendar month (16%p.a).

NOTE 10. BORROWINGS *(CONTINUED)*

R&D Loan facility

On 9 August 2024, the Company entered into a new R&D Term Loan Facility of $1,120,000 with Mitchell Asset Management Pty Ltd ("MAM"), which was advanced as a prepayment of forecast Research and Development Tax Incentives that are anticipated to be receipted by the Company for the 30 June 2024 and 30 June 2025 financial years. The facility attracts interest at 18% per annum. $600,000 of the principal is due upon receipt of the 2024 R&D Tax Incentive refund with the balance secured by the 2025 R&D Tax Incentive Refund due by 31 October 2025.

Repayment of Borrowings
Subsequent to period end, Cardiex received its 2024 R&D Tax Incentive refund totalling $1.46m. The funds were used to fully repay the working capital loan facility and partially repay the R&D Term Loan Facility, which subsequently has a reduced principal balance of $0.73m. Cardiex are currently reviewing its ongoing R&D funding options, with the forecasted 2025 R&D Tax Incentive refund expected to be in line with the 2024 refund.

NOTE 11. ISSUED CAPITAL

(a) Ordinary shares

	31 Dec 2024		30 Jun 2024	
	Shares (No)	**$**	**Shares (No)**	**$**
Ordinary shares	405,230,538	$ 97,618,506	294,174,568	$ 88,108,332
	405,230,538	**$ 97,618,506**	**294,174,568**	**$ 88,108,332**

Movements in ordinary shares:

	Shares (No)	$
Balance as at 1 July 2023	143,465,521	76,615,802
Ordinary shares issued on equity capital raise	100,000,004	8,000,000
Ordinary shares issued on conversion of convertible notes	45,250,000	3,620,000
Shares issued in lieu of payments to suppliers	1,366,724	157,299
Shares issued in lieu of payments to employees	1,220,516	97,642
Shares issued in lieu of payments for intangible assets	2,871,803	229,744
Cost of raising capital	-	(612,155)
Balance as at 30 June 2024	**294,174,568**	**88,108,332**
Ordinary shares issued on equity capital raise	32,500,000	2,925,000
Shares issued on conversion of Funding Commitment Agreement	75,000,000	6,000,000
Shares issued on exercise of performance rights	2,250,000	691,875
Shares issued in lieu of payments to employees	932,836	79,291
Shares issued in lieu of payments to suppliers	373,134	29,851
Cost of raising capital	-	(215,843)
Balance as at 31 December 2024	**405,230,538**	**97,618,506**

Ordinary shares participate in dividends and the proceeds on winding up of the Company in proportion to the number of shares held. At the shareholders meetings each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands.

NOTE 11. ISSUED CAPITAL *(CONTINUED)*

(b) Performance rights on issue

	31 Dec 2024		30 Jun 2024	
	No of Rights	$	No of Rights	$
At the beginning of reporting period	6,750,000	387,603	22,800,000	3,660,806
Rights expired during the year	-	-	(16,050,000)	-
Rights exercised during the period	(2,250,000)	(691,875)	-	-
Rights vesting expense during the period	-	493,665	-	14,973
Transfer to retained earnings	-	-	-	(3,288,176)
Closing balance at reporting date	**4,500,000**	**189,393**	**6,750,000**	**387,603**

Details of performance rights outstanding relating to Directors that were issued with shareholder approval on 16 December 2022 under the Company's Performance Rights and Options Plan are as follows:

Number of performance rights	Vesting conditions	Issue Date	Expiry Date
2,250,000	Vest upon the Company successfully achieving a Secondary Listing on a US exchange	16/12/2022	30/11/2027
2,250,000	Vest upon the Company achieving an audited $20 million in Revenue from third parties in any financial year prior to the expiry date	16/12/2022	30/11/2027

(c) Options on issue

	31 Dec 2024		30 Jun 2024	
	No of Options	$	No of Options	$
At the beginning of reporting period	94,891,539	1,872,940	24,866,499	2,210,913
Free attaching options (1 for 3) as attaching to placement	-	-	76,416,851	-
Free attaching options (1 for 1) as attaching to placement	32,500,000	-	-	-
Options issued to Directors	-	-	2,000,000	-
Options issuable for convertible notes	-	-	4,990,000	100,953
Options vesting expense	-	158,418	-	101,086
Expired and lapsed options	-	-	(13,381,811)	(540,012)
Closing balance at reporting date	**127,391,539**	**2,031,358**	**94,891,539**	**1,872,940**

NOTE 12. ACCUMULATED LOSSES

		31 Dec 2024		30 Jun 2024
Opening balance	$	(86,690,690)	$	(83,753,513)
Loss for the period		(6,973,605)		(6,765,365)
Transfer of expired options from share-based payments reserve		-		3,828,188
	$	**(93,664,295)**	**$**	**(86,690,690)**

NOTE 13. EVENTS AFTER THE REPORTING PERIOD

Subsequent to the balance date the Group announced the following material events:

- On 9 January 2025, Cardiex received its 2024 R&D Tax Incentive refund totalling $1.46m. The funds were used to fully repay the Group's working capital loan facility and partially repay the R&D Term Loan Facility.
- On 23 January 2025, Cardiex announced that deliveries to customers of CONNEQT Pulse units had commenced upon receipt of the first 3,000 units from manufacturing partner, Andon.

No other significant subsequent event has arisen that significantly affects the operations of the Group.

NOTE 14. OPERATING SEGMENTS

In the half year 2025 financial period, the Group operated in one operating segment and has identified only one reportable segment being sales of cardiovascular devices and services to hospitals, clinics, research institutions and pharmaceutical companies.

Geographically, the Group prepares information based on the location of its customers, being:

- Americas (includes global pharmaceutical trials business)
- Europe (includes Middle East and Africa)
- Asia Pacific (includes Asia & Australia/NZ)

Geographical information:

31 December 2024	Americas	Europe	Asia Pacific	Inter-segment eliminations/ unallocated	Consolidated
	$	$	$	$	$
Sales to external customers	929,531	173,070	532,816	-	1,635,417
Intersegment sales	-	-	1,076,718	(1,076,718)	-
Total sales revenue	929,531	173,070	1,609,534	(1,076,718)	1,635,417
Other income	793,155	-	864,497	-	1,657,652
Total segment revenue/income	1,722,686	173,070	2,474,031	(1,076,718)	3,293,069
Segment profit/(loss) before income tax	**(3,418,554)**	**161,621**	**(3,757,348)**	**40,676**	**(6,973,605)**
Income tax expense					-
Loss for the period					**(6,973,605)**
Segment assets	11,202,688	-	91,010,076	(85,226,010)	16,986,754
Segment liabilities	48,348,697	-	64,666,353	(102,628,741)	10,386,309

31 December 2023	Americas	Europe	Asia Pacific	Inter-segment eliminations/ unallocated	Consolidated
	$	$	$	$	$
Sales to external customers	9,162,444	187,140	121,512	-	9,471,096
Intersegment sales	-	-	-	-	-
Total sales revenue	9,162,444	187,140	121,512	-	9,471,096
Other income	541,101	-	508,424	-	1,049,525
Total segment revenue/income	9,703,545	187,140	629,936	-	10,520,621
Segment profit/(loss) before income tax	**3,859,210**	**51,293**	**(3,979,376)**	**876,127**	**807,254**
Income tax expense					-
Profit for the period					**807,254**
Segment assets	16,718,474	-	82,257,200	(82,109,300)	16,866,374
Segment liabilities	43,398,456	-	70,955,382	(97,509,176)	16,844,662

NOTE 14. OPERATING SEGMENTS *(CONTINUED)*

Inter-segment transfers

Segment revenues, expenses and results include transfers between segments. The group transfer inventory and finished goods between its group companies. Such transfers are priced on an "arm's-length" basis and are eliminated on consolidation.

Disaggregation of revenue

31 December 2024	Americas	Europe	Asia Pacific	Consolidated
	$	$	$	$
Sale of goods	697,662	169,072	528,593	1,395,327
Lease revenue	127,444	-	-	127,444
Service revenue	83,210	1,492	986	85,688
Freight revenue	21,215	2,506	3,237	26,958
Total sales revenue	929,531	173,070	532,816	1,635,417
Other income	793,155	-	864,497	1,657,652
Total revenue/income	1,722,686	173,070	1,397,313	3,293,069

31 December 2023	Americas	Europe	Asia Pacific	Consolidated
	$	$	$	$
Sale of goods	1,212,471	184,975	109,882	1,507,328
Lease revenue	7,866,924	-	-	7,866,924
Service revenue	63,506	-	9,023	72,529
Freight revenue	19,543	2,165	2,607	24,315
Total sales revenue	9,162,444	187,140	121,512	9,471,096
Other income	541,101	-	508,424	1,049,525
Total revenue/income	9,703,545	187,140	629,936	10,520,621

Segment revenue

There was no significant concentration of revenue attributable to one customer in 6 months to 31 December 2024. $7.67m of the revenue generated in the 6 months to 31 December 2023 related to the cancelled Clinichain clinical trial.

NOTE 15. CONTINGENT LIABILITIES AND CONTINGENT ASSETS

The Group has no material contingent liabilities or contingent assets as at 31 December 2024 (30 June 2024: $Nil).

NOTE 16. FAIR VALUE MEASUREMENT

Fair value measurement hierarchy

The following tables detail the Group's assets and liabilities, measured or disclosed at fair using a three-level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

- Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and
- Level 3: Unobservable inputs for the asset or liability. Considerable judgement is required to determine what is significant to fair value and therefore which category the asset or liability is placed in can be subjective.

NOTE 16. FAIR VALUE MEASUREMENT *(CONTINUED)*

31 December 2024	Level 1 $	Level 2 $	Level 3 $	Total $
Assets				
Convertible notes	-	-	4,486,773	**4,486,773**
Shares at FVTPL	-	-	462,780	**462,780**
Total Assets	**-**	**-**	**4,949,553**	**4,949,553**
Liabilities				
Promissory note	-	-	2,568,344	**2,568,344**
Total Liabilities	**-**	**-**	**2,568,344**	**2,568,344**

30 June 2024	Level 1 $	Level 2 $	Level 3 $	Total $
Assets				
Convertible notes	-	-	4,870,169	**4,870,169**
Shares at FVTPL	-	-	392,854	**392,854**
Total Assets	**-**	**-**	**5,263,023**	**5,263,023**
Liabilities				
Promissory note	-	-	2,347,751	**2,347,751**
Total Liabilities	**-**	**-**	**2,347,751**	**2,347,751**

There were no transfers between levels during the financial year.

The carrying amounts of trade and other receivables are assumed to approximate their fair value due to their short-term nature.

The fair value of financial liabilities is estimated by discounting the remaining contractual maturities are the current market interest rate that is available for similar financial liabilities.

The following valuation techniques are used for instruments categorised in Level 3:

- Convertible notes (Level 3) – The Group's holding of convertible notes issued by inHealth are classified as loans held at FVTPL. The Group obtained a third-party valuation of inHealth for the year ended 30 June 2024, which used a Monte Carlo Simulation to value the assets. The same valuation metrics were used by management to calculate the fair value of the convertible notes at 31 December 2024.
- Shares in inHealth (Level 3) – The fair value of this investment was also determined from the third party valuation that was obtained.

	Shares in inHealth $	inHealth convertible note $	Total $
Balance at 1 July 2023	**510,167**	**5,558,069**	**6,068,236**
Interest income	-	255,262	255,262
Foreign exchange adjustment	11,993	(24,611)	(12,618)
Fair value adjustment	(129,306)	(918,551)	(1,047,857)
Balance at 30 June 2024	**392,854**	**4,870,169**	**5,263,023**
Foreign exchange adjustment	28,405	276,166	304,571
Fair value adjustment	41,521	(659,562)	(618,041)
Balance at 31 December 2024	**462,780**	**4,486,773**	**4,949,553**

NOTE 16. FAIR VALUE MEASUREMENT *(CONTINUED)*

Critical estimates and judgements

Fair value measurement hierarchy

The consolidated entity is required to classify all assets and liabilities, measured at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date; Level 2:

Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3: Unobservable inputs for the asset or liability. Considerable judgement is required to determine what is significant to fair value and therefore which category the asset or liability is placed in can be subjective.

The fair value of assets and liabilities classified as level 3 is determined by the use of valuation models. These include discounted cash flow analysis or the use of observable inputs that require significant adjustments based on unobservable inputs.

NOTE 17. RELATED PARTY TRANSACTIONS

Funding Commitment Agreement

On 3 November 2023, Cardiex entered into a Funding Commitment Agreement (FCA) with C2V to provide up to $7.5 million to support the funding needs of the Company, which was subsequently revised to a total committed contribution of $8,466,434 on 14 March 2024 to provide for additional funds contributed by C2V by way of underwriting an Entitlement Offer in February 2024.

Key terms of the Funding Commitment Agreement are:

- An interest rate of 10% applies on all principal outstanding amounts contributed via the facility.
- The Facility Limit is reduced by amounts advanced to, loaned to, owed by or received by the Company from C2V and related parties, including under the proposed Placement and Entitlement Offer.
- Cardiex may require C2V (or its nominee) to advance a loan under the loan facility at any time between the date of the Agreement and 31 December 2024 (or such later date as is agreed between the parties) by giving notice to the Lender. If such shareholder approval is not obtained under the Shareholder Approval of Conversion clause the C2V may terminate its obligation to provide further loans under the loan facility.
- Subject to all necessary board, shareholder and regulatory approvals, some or all of the outstanding moneys may be repaid by the Company by issuing securities to the C2V, such as under the proposed Placement and Entitlement Offer.
- The Company convened a shareholder meeting to seek approval, to the extent possible, for the conversion to equity of all loans under the loan facility, up to the maximum Facility Limit. Shareholder approval was subsequently received at an Extraordinary Meeting held on 3 June 2024:
- Interest will accrue on the principal outstanding at 10% per annum during the period commencing on the date of the FCA and ending on, if shareholder approval is not obtained to convert loans into equity, the day of the shareholders meeting; and otherwise, the Maturity Date. If shareholder approval is not obtained, 15% per annum during the period commencing on and from the day after the shareholder meeting and ending on the Maturity Date. The Company may elect whether to pay interest in cash. If interest is not paid in cash, it will automatically be capitalised.
- The Company may at any time prepay all or part of the outstanding moneys without premium or penalty.
- If, after 31 December 2025 there are any outstanding moneys, the Company must repay the outstanding moneys at the request of the Lender, on at least 30 days' notice. The Lender may only request repayment, or seek to enforce recovery of outstanding moneys, to the extent that the payment can be paid or satisfied from the available assets of the Company following payable of the Company's other liabilities.
- It is an event of default if the Company fails to pay or repay any amount due under the agreement when due, or an event of insolvency occurs in respect of the Company. If an event of default occurs and is subsisting, the Lender may terminate its obligation to provide further loans under the loan facility and/or declare outstanding moneys due and payable.

Subsequent to the signing of the FCA and variation agreements, an EGM was held on 3 June 2024, seeking approval of the transaction, including a Debt to Equity Conversion Agreement, which was executed on 3 June 2024 post shareholder approval.

NOTE 17. RELATED PARTY TRANSACTIONS *(CONTINUED)*

Key terms of the Debt to Equity Conversion Agreement were:

- Any prior amounts contributed to the FCA that have been repaid or converted to equity will not form part of the Principal Outstanding.
- A conversion limit of $6,000,000.
- Providing Cardiex with the right to convert any principal outstanding to equity on the same terms.
- Providing C2V and the Cardiex with a right to convert any principal outstanding amounts prior to the expiry of the FCA.
- On conversion of debt to equity by either C2V or Cardiex, C2V will be issued in satisfaction of the relevant amount of Principal Outstanding a number of Shares equal to the conversion amount divided by $0.08. Every 3 conversion shares issued will also entitle C2V to have the benefit of 1 Quoted Option. This represents a maximum of 75,000,00 Conversion Shares may be issued if the FCA is fully drawn.
- The issuance of 25,000,000 Quoted Options to C2V, which will have the same terms and conditions as the Company's existing class of Quoted Options, but will be subject to a contractual restriction on C2V exercising, selling, transferring, using as collateral, or otherwise disposing of those Quoted Options except to the extent that an appropriate number of Conversion Shares are issued.

At the beginning of the current period, there was $6,000,000 available to Cardiex on the FCA facility, noting all prior amounts contributed were settled in February 2024 from participation in a capital placement and an Entitlement Offer. During the period, $6,000,000 was contributed to Cardiex by C2V from the FCA, and all amounts were converted via the issue of 75,000,000 shares on 30 December 2024.

Below is a summary of the movement of the FCA facility in the current period.

Period	Facility movement ($)
Cash contributions received in the period	5,478,766
Settlement of Director payments in the period	521,234
75,000,000 conversion shares issued at $0.08 on 30 December 2024	(6,000,000)
Balance of FCA at 31 December 2024	-

NOTE 18. CONTROLLED ENTITIES

The consolidated financial statements include the financial statements of Cardiex Limited. and the following subsidiaries:

Name	Country of incorporation	Beneficial interest (%)*	
		31 Dec 2023	30 Jun 2023
AtCor Medical Pty Limited	Australia	100	100
AtCor Medical Inc	USA	100	100
Cardiex (Shanghai) Medical Technology Co., Ltd.	China	100	100
Conneqt Inc	USA	100	100

**Percentage of voting power is in proportion to ownership.*

NOTE 19. CAPITAL COMMITMENTS

There were no other commitments as at 31 December 2024.

NOTE 20. COMPANY DETAILS

The registered office of the Company is:

Cardiex Limited
Suite 301, Level 1
55 Lime Street
Sydney NSW 2000

The principal place of business is:

Cardiex Limited
Suite 301, Level 3
55 Lime Street
Sydney NSW 2000

DIRECTORS' DECLARATION

The Directors of the Company declare that:

(a) in the directors' opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable;
(b) in the directors' opinion, the attached financial statements are in compliance with International Financial Reporting Standards, as stated in Note 1 to the financial statements;
(c) in the directors' opinion, the attached financial statements and notes as set out on pages 12 to 28 comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements; and
(d) the attached financial statements and notes thereto give a true and fair view of the consolidated entity's financial position as at 31 December 2024 and of its performance for the financial half-year ended on that date.

Signed in accordance with a resolution of the directors made pursuant to s303 (5) (a) of the Corporations Act 2001.

On behalf of the Directors:

Niall Cairns
Executive Chairman
Sydney, 28 February 2025

Tel: +61 2 9251 4100
Fax: +61 2 9240 9821
www.bdo.com.au

Level 11, 1 Margaret Street
Sydney NSW 2000
Australia

INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of CardieX Limited

Report on the Half-Year Financial Report

Conclusion

We have reviewed the half-year financial report of CardieX Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2024, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, material accounting policy information and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

i. Giving a true and fair view of the Group's financial position as at 31 December 2024 and of its financial performance for the half-year ended on that date; and
ii. Complying with Accounting Standard AASB *134 Interim Financial Reporting and the Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be the same terms if given to the directors as at the time of this auditor's review report.

Material uncertainty relating to going concern

We draw attention to Note 1 in the financial report which describes the events and/or conditions which give rise to the existence of a material uncertainty that may cast significant doubt about the Group's ability to continue as a going concern and therefore the Group may be unable to realise its assets and discharge its liabilities in the normal course of business. Our conclusion is not modified in respect of this matter.

Responsibility of the directors for the financial report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is true and fair and is free from material misstatement, whether due to fraud or error.

Auditor's responsibility for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including giving a true and fair view of the Group's financial position as at 31 December 2024 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting and the Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BDO Audit Pty Ltd

BDO

Tim Aman
Director

Sydney, 28 February 2025